Rationale: As the third leading cause of death in the United States, the impact of chronic obstructive pulmonary disease (COPD) makes identification of its molecular mechanisms of great importance. Genome-wide association studies (GWASs) have identified multiple genomic regions associated with COPD. However, genetic variation only explains a small fraction of the susceptibility to COPD, and sub-genome-wide significant loci may play a role in pathogenesis.
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction and is the third leading cause of death in the United States (1) . Genetic association studies have identified multiple genomic regions that explain only a small fraction of the heritability of COPD; epigenetic association studies in blood and lung tissue have likewise identified associations with COPD affection status.
Given that an environmentally influenced complex disease like COPD is driven by both genetic and epigenetic variation, understanding the genetic control of DNA methylation in lung tissue may highlight the regulatory contributions relevant to COPD pathogenesis, using results from prior genome-wide association studies (GWASs) as a guide.
Loci associated with complex disease traits are enriched with epigenetic annotations including DNA methylation (2) and have a role in gene regulation, complex traits, and human development (3, 4) . DNA methylation profiling may uncover molecular targets for lung disease perturbed by environmental exposures, such as smoking (5-7) or medications (8) , that may also be found suggestive in genetic association studies but not within stringent statistical thresholds adjusting for genome-wide multiple testing. Prioritization of previously identified genomic loci will enhance the molecular understanding of complex disease (9, 10) . Genetic control of DNA methylation has been observed in diabetes (11) , schizophrenia (12) , complex traits such as blood pressure and body mass index (13, 14) , and various complex diseases (15) . In these contexts, genetic-epigenetic interactions may be linked to the perturbation of regulatory elements, such as transcription factor binding (15, 16) and changes in gene expression (11, 14, 15, 17, 18) , potentially with allele-specific effects (19, 20) .
Recent studies have demonstrated associations between COPD affection status and DNA methylation in lung (21, 22) and small airway (23) tissues. Cigarette smoke exposure has been associated with DNA methylation variability in the lung (21) and small airways (24) . Genetic control of DNA methylation in normal lung tissue (25) and the association of DNA methylation with gene expression in the lungs of subjects with COPD (22, 26) and small airways (23) have also been demonstrated. The genetic control of DNA methylation is observed by testing the association between SNP variants and DNA methylation via methylation quantitative trait loci (mQTL) analyses. cis-mQTL analysis involves associations in local genomic regions, whereas trans-mQTL analysis involves genome-wide associations. Intersecting mQTL results in normal lung tissue with statistically significant GWAS loci have provided regulatory annotation for lung cancer genes (25) and support the need to investigate the regulatory role of genomewide DNA methylation in the context of nonneoplastic lung diseases such as COPD. Intersecting whole-blood mQTL results with DNA methylation sites associated with smoke exposure (5) highlighted disease susceptibility factors in the context of environmental exposure and suggested that genetic control of methylation, in addition to smoke exposure and other genetic influences, likely plays a role in COPD pathogenesis.
In this study of genetic control of methylation, we performed cis-mQTL analysis in lung tissue from severe COPD cases and ex-smoker control subjects and integrated the findings with prior results from a GWAS (27) and an epigenome-wide association study (EWAS) of COPD (22) using the Infinium HumanMethylation450 BeadChip. We used Bayesian colocalization methods (28) previously applied to mQTL for schizophrenia (12) to test the hypothesis that genetic variants associated with DNA methylation influence COPD pathogenesis and susceptibility. Genetic loci that do not meet genome-wide significance (subthreshold results) may play a role in complex diseases (29) such as COPD. We include these subthreshold loci, as they may be given priority in further investigations based on our methods, absent higher-powered genetic association studies with thousands more subjects. This study in lung tissue provides regulatory information for COPD GWAS loci and informs selection of genomic loci for future in vitro validation studies. Some of the results of these studies have been previously reported in the form of an abstract (30) .
Methods
Lung tissue samples were collected from subjects undergoing thoracic surgery for lung transplantation, lung volume reduction surgery, or lung nodule resection at three medical centers: Brigham and Women's Hospital (Boston, MA), St. Elizabeth's Hospital (Boston, MA), and Temple University Hospital (Philadelphia, PA). Institutional review board approval was obtained at the three centers, and subjects provided written informed consent. All subjects were former smokers by self-report who quit smoking at least 1 month before thoracic surgery (22, 31) . Subjects with
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Scientific Knowledge on the Subject: Genome-wide association studies (GWASs) have identified multiple genomic regions associated with chronic obstructive pulmonary disease (COPD). However, genetic variation only explains a small fraction of the susceptibility to COPD. Given that an environmentally influenced complex disease like COPD is driven by both genetic and epigenetic variation, understanding the genetic control of DNA methylation in lung tissue may highlight regulatory components of COPD pathogenesis. We include subthreshold GWAS loci, as they may play a role in COPD and may be given priority in further investigations based on our methods, absent higher-powered genetic association studies.
What This Study Adds to the Field: Our integrative analyses using DNA methylation profiling and genome-wide genotyping from lung tissue samples from COPD cases and control subjects, and subsequent Bayesian colocalization with previous COPD GWAS findings, highlight potential regulatory features of the loci, supporting a role for genetic control of methylation in COPD pathogenesis. Our top candidate gene KCNK3 was near subthreshold loci and could rise to significance in larger GWAS of lung disease, as we provided similar molecular justification for EEFSEC, a gene that has only recently been validated by virtue of its proximity to a genome-wide significant locus in a large study. Our methods have also revealed regulatory mechanisms near loci previously associated with COPD. . Batch_number is a methylation data batch variable, and batch_PCs represents the methylation principal components described below. We performed 10 analyses after randomly permuting the subject labels on the methylation data and covariates each time. Using the P values from these 10 permutations and our mQTL results, we determined that a P value of 3.2 3 10 26 corresponds to a false discovery rate (FDR) of 5% (15, 33) . A significant association with P value below this threshold is presented as an mSite (CpG site) and mQTL (SNP) pair. Before these analyses, an iterative method was used to determine the number of principal components for the matrix of b values to add as covariates to mitigate batch effects. This procedure involves finding the number of principal component covariates that produces a maximum number of significant (FDR , 0.05) cis-mQTL (window of 1 Mb). We used linkage disequilibrium-pruned genotyping data (r 2 threshold of 0.3) from chromosomes 21 and 22 (31) . The maximum was achieved with 10 PCs, and these were included as additional covariates in the mQTL analyses.
GWAS and mQTL Colocalization
For integration with GWAS, results were extracted from a published COPD case-control GWAS (27) at P value thresholds of 0.05, 10 24 , and 5 3 10 28 . The total number of SNPs meeting these thresholds was 456,214, 2,252, and 298, respectively. Annotations on the basis of gene proximity for these SNPs were obtained from the Ensembl database (GRCh37) using the R package biomaRt (34) . The colocalization of mQTL and GWAS results in local cis regions was assessed using the R package coloc, which highlights several posterior probabilities (PP) for consideration (28) . This Bayesian framework is used to determine if an overlap of mQTL and GWAS associations is consistent with a shared causal variant. For each CpG mSite, all imputed SNPs in the lung tissue data that overlap with the GWAS and that also have nominal association (P , 0.05) with the mSite are included in the colocalization assessment. The effective window size for these SNPs is 1 million bases. A larger value for the PP4 indicates a higher probability of a shared causal variant (fourth hypothesis of the coloc method), implying colocalization in the region for the two association Definition of abbreviations: Chr = chromosome; coord = coordinate; mQTL = methylation quantitative trait loci; NA = not available; rsID = reference SNP ID number.
Results for the most significant mQTL/SNP only. *This mSite and a different significant mQTL were associated in a previous normal lung tissue cis-mQTL analysis (false discovery rate , 5%) (25) . † This mSite and mQTL association identified in previous normal lung tissue cis-mQTL analysis (false discovery rate , 5%) (25) .
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profiles. A larger PP3 value indicates a higher probability of separate mQTL and GWAS associations (28) . In addition to the value of PP4, the ratio of PP4 to PP3 may also be used as an indicator of colocalization significance, with a ratio greater than five suggesting a strong shared signal over strong individual signals (12, 35) .
Results
DNA methylation data were available for lung tissue from 90 patients with severe COPD (mean FEV 1 , 26.1% predicted) and 36 control subjects with normal spirometry (see Table E1 in the online supplement). There were no significant differences between cases and control subjects by sex or age. The COPD cases had higher cumulative pack-years of cigarettes smoked and quit smoking more recently, on average 8 fewer years in the past (P = 0.0002).
mQTL
Using the DNA methylation profiling and imputed genotyping data for lung tissue from the white cases and control subjects, we performed a cis-mQTL analysis, testing for SNPs associated with DNA methylation levels. We identified 942,068 unique mQTL and 33,996 unique mSites (5% FDR). The mQTL and mSites are the significant SNPs and CpG sites from the mQTL analysis, respectively. This represents 17% of the SNPs and 10% of the CpG sites tested. We intersected these results with a previous study of mQTL in normal tissue (25) . Of the 26,564 statistically significant CpG sites from the Shi and colleagues study in our final DNA methylation data, 15,649 are found among our significant results (59%) (25) . Our top results, selecting the most significantly associated mQTL for each CpG mSite, are shown in Table 1 (5% FDR, Manhattan and volcano plots in Figure 1 ). We found replication for 11 of these 20 mSites in the Shi and colleagues study; four also had the same associated mQTL (25) . We examined the distribution of CpG island location annotations (36) for the 33,996 significant CpG mSites ( Figure E1) ; 11,719 mSites do not have an island-related annotation. Significant enrichment in the shore and shelf regions was observed (hypergeometric test P value , 0.0001). Of the 9,055 genes in the annotation of the 33,996 mSites, 478 have significant (hypergeometric test, FDR q value , 0.05) mSite enrichment (Table E2) , when using the number of CpG sites assayed for each gene as the reference. Among these 478 multi-mSite genes, 36 were from the MHC (major histocompatibility complex) region (bases 29,640,000 to 33,120,000 on chromosome 6). Pathway analysis using the KEGG (Kyoto Encyclopedia of Genes and Genomes) database and ConsensusPathDB (37) revealed enrichment for immune system pathways and diseases, including asthma (Table E3 ). These enrichments for CpG sites with genetic associations suggest that genetic control of methylation may be more pronounced for some genes or genomic regions.
Disease Relevance of mQTL
We intersected all 811,739,658 cis-mQTL results with the previously published COPD case-control GWAS (27) results (P , 0.05; see METHODS) by the rsIDs of the SNPs/mQTL, and the overlapping SNP count was 277,643. A scatter plot of the cis-mQTL P values (Figure 2 ) with an overlay of COPD EWAS significance (22) graphically highlights the CpG mSites and mQTL with prior COPD associations. We observed that mQTL with COPD GWAS associations generally are not associated with CpG sites identified in the COPD EWAS, as regions of at least subthreshold GWAS associations (P , 10 24 ) and significant mQTL P values are effectively devoid of significant (FDR , 5%) EWAS CpG sites. We performed a two-way intersection of the significant mQTL results (FDR , 5%) and COPD GWAS (27) (P , 10 24 ) using SNP/mQTL rsIDs. Of the 2,252 subthreshold GWAS SNPs, a total of 1,847 were found in the lung imputed genotyping data. The mQTL-GWAS overlapping SNP count was 753 of the 1,847; these GWAS results were enriched in mQTL (hypergeometric test P value , 0.00001, fold enrichment = 2.5). This intersection sorted by mQTL P value, selecting the most significant mQTL for each CpG mSite, is shown in Table E4 ; 34 of these 73 mSites were significant in the Shi and colleagues study (25) . With respect to CpG island location annotation, there was suggestive evidence of north shore enrichment (P , 0.15; Figure E2 ) among the mSites from this intersection with GWAS. In addition, CpG mSites annotated to the genes NUPR1 and CYP2A7 were present in this intersection. These two genes were also significantly enriched for mSites (Table E2) . For the intersection with only genome-wide significant (P , 5.0 3 10 28 ) GWAS (Table  E5) , 155 of the 297 significant GWAS SNPs found in the imputed lung genotyping data were in the intersecting set. This intersection highlights several COPD genes previously identified based on their proximity to the significant GWAS SNPs. In addition, 7 of the 12 CpG mSites in Table E5 were significant in the Shi and colleagues study (25) . These overlaps with GWAS motivated further investigation of colocalization using Bayesian methods to hone in on the more robust COPD loci.
Colocalization of the mQTL and GWAS Associations
We tested whether the mQTL and GWAS associations were colocalized (see METHODS). Colocalization of mQTL with COPD GWAS loci would suggest a genetic control of methylation with disease relevance and would highlight a possible regulatory role in COPD GWAS loci. All 73 significant (FDR , 5%) CpG mSites with mQTL intersecting subthreshold (P , 10 24 ) GWAS (27) were assessed for colocalization. PP4 values of 0.9 and greater that have PP4/PP3 greater than 5 are considered to be significant, as those values support a single shared causal variant ( Table 2) . Nine of the 20 mSites with suggestive evidence of colocalization were significant in the Shi and colleagues study (25) .
A CpG mSite in DNase hypersensitivity (DHS) and enhancer regions annotated to KCNK3 (cg11273176) has significant evidence of colocalization with subthreshold GWAS (PP4 = 0.959, and PP4/PP3 . 10; Tables 2 and E6 and Figure 3 ). The LocusZoom plots (Figure 4) provide convincing support for a shared genetic association profile. Several findings in Table 2 were not previously annotated to a specific gene, although they highlight genes and regions of interest. For example, a CpG mSite upstream of TCERG1L (cg19961228) on chromosome 10 has strong colocalization evidence ( Figure E3 ). Two mSites (cg27091865 and cg17052675) on chromosome 2 with significant colocalization are located in the gene DCDC2C and in a region of putative CTCF Binding (regional summary, Figures E4 and E5, Table E6 ). Although the effects of DNA methylation on CTCF binding are unclear, the potential impact on chromatin architecture, DNA folding, and gene regulation (4, 38) could have significant implications in disease. On chromosome 12, the CpG mSite cg13890972 demonstrates colocalization with prior GWAS ( Figure E6 ) and is located in the gene CCDC91, and is also in a DHS region characterized as having open chromatin (Table E6 ). The mSite cg05515099 on chromosome 3 is located in the gene FRMD4B and is also located in a DHS region ( Figure E7 , Table E6 ). A significant mSite on chromosome 17 (cg13527508) is located in DHS and promoter flanking regions and is downstream of the gene RAP1GAP2 ( Figure  E8 , Table E6 ).
One mQTL (Table 2 ) is a genome-wide significant SNP from the prior COPD GWAS. This SNP is annotated by proximity to the previously identified GWAS gene CHRNA5 (rs11633958, chr15). However, the colocalization in this region highlights a CpG mSite (cg04882995) annotated to the gene CHRNA3 (mSite-SNP distance 50,594 bases; Figure E9 ). The mSite is located in an open chromatin and DHS region with putative transcription factor binding (Table E6) .
The colocalization results for EEFSEC are an example of a subthreshold GWAS association with additional supportive evidence. The results for two mSites annotated to EEFSEC (cg08044714 and cg05377949) have suggestive colocalization (PP4 . 0.8 and PP4/PP3 . 4; Table 2 and Figure E10 ), and cg05377949 is located at a DHS region (Table E6 ). LocusZoom plots of association results from the mQTL analysis and prior GWAS ( Figure E11 ) illustrate similar P-value profiles, as expected with suggestive colocalization. A CpG mSite (cg26573321) annotated to PIK3CD on chromosome 1 demonstrates strong colocalization (Table 2 and Figure  E12 ). This mSite is in a promoter and DHS region (Table E6) . Last, the complex region on chromosome 16 ( Figure E13 ) near the genes SULT1A2 and NUPR1 has several CpG mSites with strong colocalization that are also located in transcription factor binding and DHS regions.
Expression Profiling for Identified Genes
We examined our previous gene expression profiling results in lung tissue samples from this study cohort (31) . For the CpG mSite gene annotations listed in Table 2 , we observed differential expression for SULT1A2 (P = 0.018) by COPD status, providing additional regulatory evidence for the complex region on chromosome 16. When we examine the additional genes identified in the colocalization regions of Table 2 , we observed differential expression of CCDC91 (P = 0.004) and FRMD4B (P = 0.014) by COPD status. In addition, we examined the association between gene expression and DNA methylation for the genes in Table 2 . We used data from the 86 cases and 34 control subjects for whom we have both DNA methylation and gene expression data and corrected for batch effects independently in each set. Associations were found for KCNK3 (cg11273176: P = 0.004; Figure E14 ) and SULT1A2 (cg01621080: P = 7.5 3 10 27 ; cg01621080: P = 0.00016; cg01621080 shown in Figure E14 ). We also observed associations for all three NUPR1 mSites (cg15149645: P = 0.0013; cg01542023: P = 0.007; and cg16576597: P = 0.0006; cg15149645 shown in Figure E14 ). These methylation-expression findings support a possible gene regulatory role for the genetic control of DNA methylation in lung tissue.
Discussion
We examined the genetic control of DNA methylation to provide regulatory annotation and prioritization of COPD GWAS loci, through integration of genomewide DNA methylation and genotyping data, and subsequent intersection with GWAS results. We observed that mQTLs are abundant in lung tissue and that many genome-wide significant loci from COPD GWAS are not mQTL. However, delving into the subthreshold GWAS findings, we found noncoding variants significantly enriched with mQTL.
Colocalization provided insight into the overlapping cis-mQTL and GWAS association profiles. The gene KCNK3 (potassium two pore domain channel subfamily K member 3) was previously suggested as a COPD gene using protein-protein interaction data (39) . The CpG mSite annotated to KCNK3 was also found in a previous normal tissue mQTL study (25) and is located in a DHS region with putative enhancer binding within the gene. The regulatory implications and genomic reach of this CpG mSite are not Definition of abbreviations: Chr = chromosome; GWAS = genome-wide association study; mQTL = methylation quantitative trait loci; PP = posterior probability; rsID = reference SNP ID number; UTR = untranslated region. The mQTL with the most significant CpG mSite association is shown. *Location relative to the first listed transcript in the complete annotation; annotations provided by assay manufacturer (36) . † mSite associated with a different mQTL in both our analysis and previous normal lung tissue cis-mQTL analysis (false discovery rate , 5%) (25) . ‡ mSite identified in previous normal lung tissue cis-mQTL analysis (false discovery rate , 5%) (25) .
currently known. However, our methylationexpression findings highlight a possible role in the regulation of KCNK3 expression. Strong colocalization evidence was observed for EEFSEC (eukaryotic elongation factor, selenocysteine-tRNA specific) at two CpG mSites. A recent COPD genome-wide association metaanalysis in more than 60,000 subjects identified genome-wide significant loci in EEFSEC (40, 41) . The statistical association of EEFSEC in this higher-powered study demonstrates the ability of our approach to elevate subthreshold results with potential relevance to COPD, without the demands of increasing sample sizes by tens of thousands.
Our study of genome-wide significant loci highlighted CHRNA3 (cholinergic receptor nicotinic alpha 3 subunit) within a locus implicated in previous COPD GWAS (27, 42) . The genes CYP2A7 (cytochrome P450 family 2 subfamily A member 7) and NUPR1 (nuclear protein 1, transcriptional regulator) were enriched in mSites and associated with an mQTL having subthreshold significance in prior GWAS. In a more recent GWAS of lung function of COPD, CYP2A7 was identified in a genome-wide significant locus on chromosome 19 (43) . A region of interest for future detailed study in COPD is located near IL27 (interleukin 27), SULT1A1, and SULT1A2 (sulfotransferase family 1A member 2). This region also includes NUPR1. The complexity and genetic relevance of this region on chromosome 16 was highlighted in an association study of exome array data in COPD (44) . The recent Hobbs and colleagues COPD meta-analysis also identified a genome-wide locus in this region of chromosome 16 (40) . Our approach may narrow the search for pathogenic genes within these complex regions identified through GWAS.
The mQTLs in this study were distributed throughout the genome. Within the top 20 mQTL results, 11 of the CpG mSites were found in a previous cis-mQTL analysis in normal lung tissue (25) ; all 11 associated mQTLs in normal tissue were found within our significant results, suggesting that some are lung QTLs important for normal function and development, but others may be driven by exposure or disease. Nine of the 20 CpG mSites in the colocalization results were significant (FDR , 5%) in the Shi and colleagues study, including the mSite annotated to CHRNA3 (25) . This, together with the replication of top colocalization findings for KCNK3, was a robust recapitulation of genetic effects on DNA methylation in lung tissue, independent of disease status.
We observed CpG island shore and shelf annotations among the significant CpG mSites, but only enrichment of CpG island northern shores is suggested, when limited to a GWAS P value threshold of 10 24 ; enrichment of northern shore sites has been previously observed (25) . This suggests that CpG mSites related to disease susceptibility via genetic effects are a subset with more regulatory implications (25, 45, 46) , and these northern-shore regions are of particular interest for functional characterization. We also observed KCNK3 site in the gene body is perhaps the opposite of what might be predicted (3), the complex regulatory effects of DNA methylation are still not fully understood (2, 48) . Together, our data support disease relevance for DNA methylation at regions of gene regulatory impact.
The limitations of our study involve the potential contribution of cellular heterogeneity that is inherent in experiments with homogenized lung tissue. Future validation of these findings in single lung cell types will address this issue. As technology advances, we will investigate DNA methylation regulatory effects in vitro to provide insight into causal mechanisms. In addition, our study focused on severe COPD. The study of other levels of severity or related COPD phenotypes, including emphysema and airway disease, will provide greater context for these findings. Last, distant normal tissue was sourced from lung nodule resection samples; although there is concern for a potential field effect from cancerous nodules, no enrichment for cancer-related gene sets was observed in our pathway analyses, which argues against such bias. Epigenetic studies complement genetic association studies to identify COPD pathogenesis genes. Our study has provided regulatory characterization of loci among significant and subthreshold GWAS results. In the case of EEFSEC, we provided molecular justification to elevate a prior subthreshold result that has only recently been validated by virtue of its proximity to a genome-wide significant locus in a large study. Other genes identified near subthreshold loci, such as KCNK3, could rise to significance in larger GWAS of lung disease, as colocalization has provided compelling evidence for this gene. As demonstrated for the CHRNA5 locus from prior COPD GWAS, the methods presented in this study may identify causal variants and reveal regulatory mechanisms in regions with loci known to be associated with COPD. Colocalization of methylation QTL and GWAS loci provides regulatory characterization of significant and subthreshold GWAS, supporting a role for genetic control of methylation in COPD pathogenesis. n Author disclosures are available with the text of this article at www.atsjournals.org.
